Med Dev
- 5 Stocks Wall Street Believes Will Stage a Remarkable Recovery in 2024 | investing.com
Fingers crossed! - Medtech can cope with GLP-1s but ‘fear and doubt’ suppressing stocks: analysts (Nick Paul Taylor)
Hmm.. "...the analysts concluded that GLP-1 drugs are very likely to disrupt medtech markets, particularly obstructive sleep apnea and cardiovascular disease." - Amazon In Healthcare: Disruption, Data Nightmares And Digital Health Dreams (Andrea Koncz)
"The amalgamation of services and the convergence of data streams within Amazon’s ecosystem presents a double-edged sword."